Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin.

FDA’s Oncologic Drugs Advisory Committee unanimously voted in favor of the ADC on July 14; GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects FDA’s decision next month (see “GSK Maintains Lead in BCMA Race”)...